SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

NACompletedINTERVENTIONAL
Enrollment

614

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

March 3, 2024

Study Completion Date

March 11, 2025

Conditions
SARS-CoV-2 InfectionInfluenza AInfluenza B
Interventions
DIAGNOSTIC_TEST

Aptitude Medical Systems Metrix COVID/Flu Test

The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.

Trial Locations (3)

35235

American Family Care, Trussville

93117

Central Coast Laboratories, Goleta

01824

American Family Care, Chelmsford

Sponsors
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Aptitude Medical Systems

INDUSTRY

NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings | Biotech Hunter | Biotech Hunter